The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Claire Lafitte
No Relationships to Disclose
 
Charles Ricordel
Consulting or Advisory Role - BMS
 
Laurent Greillier
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD; Roche
 
Jean-Louis Pujol
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); ROCHE (Inst); Roche (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
Charlotte Domblides
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Jeannick Madelaine
No Relationships to Disclose
 
Jaafar Bennouna
Honoraria - Amgen; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; roche; SERVIER
Consulting or Advisory Role - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Celine Mascaux
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Kephren; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche; Takeda
 
Denis Moro-Sibilot
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly/ImClone; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim France (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Expert Testimony - MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly/ImClone; MSD Oncology; Pfizer; Roche/Genentech
 
François Pinquié
Honoraria - AstraZeneca; Roche
Travel, Accommodations, Expenses - Takeda
 
Alexis Cortot
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche; Takeda
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Josiane Otto
No Relationships to Disclose
 
Jacques Cadranel
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Novartis (Inst); Pfizer (Inst)
 
Alexandra Langlais
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Virginie Westeel
Leadership - Bristol-Myers Squibb; Roche; Takeda
Honoraria - MSD Oncology
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Pfizer; Roche
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cergentis (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst)